Table 2.

Clinical characteristics and treatments of SARS in 2003.

	S/CO>1n = 29	S/CO ≤ 1n = 24	P value
Male sex (%)	3 (10.3%)	5 (20.8%)	0499
Age (years)	47.12 ± 1.81	47.3 9± 1.69	0.914
Clinical symptoms, n (%)
Fever	29 (100%)	24 (100%)	–
Duration of fever(days)	9.00 (6.50-14.50)	7.00 (5.00-15.00)	0.798
Rigor	21 (77.8%)	12 (50%)	0.039
Myalgia	21 (77.8%)	13 (54.2%)	0.074
Cough	14 (51.9%)	12 (50%)	0.895
Dyspnoea	17 (63%)	14 (58.3%)	0.735
Vomiting	6 (22%)	2 (8.3%)	0.329
Diarrhoea	5 (18.5%)	4 (16.7%)	1.000
Treatments
Total Methylprednisolone (mg)	3500 (2240-9872)	4575 (2350-15000)	0.491
Immunoglobulin	12 (44.4%)	6 (25%)	0.228
Thymosin	21 (77.8%)	12 (50%)	0.038
Severity
ARDS	9 (33.3%)	4 (16.7%)	0.173
Lung injury	11 (37.9%)	7 (29.2%)	0.502
Bone injury	5 (17.2%)	8 (33.3%)	0.175
SCAP	12 (41.4%)	10 (41.7%)	0.983

S/CO>1: presence of SARS-CoV-2 IgG antibodies via a chemiluminescence microsphere immunoassay; S/CO ≤ 1: devoid of SARS-CoV-2 antibodies via a chemiluminescence microsphere immunoassay; Data are presented as means ± standard error from the mean, or median (interquartile range) or n (%). ARDS, acute respiratory distress syndrome; SCAP, severe community acquired pneumonia.

The bold value mean that P value <0.05 and were statistically significant.